Ventriculoperitoneal (VP) shunts malfunction at alarmingly high rates, with upwards of 40% failing within the first year of placement. Such malfunctions are notoriously difficult to diagnose (or rule out) and can be devastating if not caught and treated quickly. Despite extensive research and development efforts by clinicians, scientists, and medical device companies, current diagnostic techniques remain burdensome, invasive, expensive – for patients and the healthcare system – and often, inaccurate and unreliable.
To address this need, Dr. Ramin Eskandari, Dr. Mohammed Alshareef, and Mr. Tyler Vasas – all at the Medical University of South Carolina – have partnered with ZIAN to develop and commercialize the AccuShunt system, which is poised to improve the lives of hundreds of thousands of patients around the world.
Via a patent pending device that leverages proprietary algorithms and the latest in ultrasound science, AccuShunt allows users to accurately, reliably, efficiently, and non-invasively determine whether a patient’s shunt has failed and the location and degree of failure.
AccuShunt will not only dramatically improve the lives of hundreds of thousands of patients, it also has the potential to prevent a large percentage of the tens of thousands of X-rays, MRIs, CTs, and surgeries that VP shunted patients undergo each year, thereby helping payors and health systems recapture a large percentage of the $250M to $2B in annual spend on those procedures.
Available for exclusive licensing or acquisition
Proof of concept, bench-testing complete using ex-vivo VP shunts
First generation prototype built, including hardware, software, user interface, and accessories
Human testing in progress, under IRB-approved protocol
International Patent Application (PCT) pending, claiming priority to previously filed U.S. Provisional Patent Application